Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: The Italian experience

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue SUPPL. 2, 2003, Pages 277-283

  Brunelli, Valeria L ^a   Russo, G ^b   Bertelloni, S ^c   Gargantini, L ^d   Balducci, R ^e   Chiesa, L ^f   Livieri, C ^f   De Sanctis, C ^g   Einaudi, S ^g   Virdis, R ^h   Saggese, G ^c   Chiumello, G ^b  

^a V BUZZI CHILDREN S HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d TREVIGLIO HOSPITAL   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

Author keywords

21 hydroxylase deficiency; Congenital adrenal hyperplasia; Final height; Glucocorticoid substitutive treatment; Growth

Indexed keywords

CORTISONE ACETATE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISONE; STEROID 21 MONOOXYGENASE;

ADULT; ARTICLE; BODY HEIGHT; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DATA ANALYSIS; DRUG FORMULATION; FEMALE; GENDER; HUMAN; HYPERANDROGENISM; ITALY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOMES RESEARCH; PHENOTYPE; SALT LOSING NEPHRITIS; STATISTICAL SIGNIFICANCE; STEROID 21 MONOOXYGENASE DEFICIENCY; VIRILIZATION; DOSE RESPONSE; GENETICS; PATHOLOGY; SEXUAL DEVELOPMENT;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; BODY HEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PHENOTYPE; SEX CHARACTERISTICS;

EID: 0141995609     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. New MI. Factors determining final height in congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2001; 14 (Suppl 2): 933-937.
2. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87: 4048-4053.
3. Kirkland RT, Keenan BS, Holcombe JH. The effect of therapy on mature height in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 47: 1320-1322.
4. Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion. J Clin Endocrinol Metab 2002; 87: 2238-2244.
5. Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SMPF, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child 2002; 87: 139-144.
6. Tanner JM, Whitehouse RH. Clinical longitudinal standards of height, weight, height velocity and stages of puberty. Arch Dis Child 1976; 51: 170-179.
7. Greco L, Numeroso V. Growth as measure of community health. Growth Matters Int 1994; 17: 10-12.
8. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001; 138: 3-5.
9. Hargitai G, Solyom J, Battelino T, Lebl J, Pribilincova Z, Hauspie R, Kovacs J, Waldhauser F, Frisch H. Growth patterns and final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Results of a multicentric study. Horm Res 2001; 55: 161-171.
10. Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 3070-3078.
11. Thilen A, Woods KA, Perry LA, Savage MO, Wedell A, Ritzén EM. Early growth is not increased in untreated, moderately severe 21-hydroxylase deficiency. Acta Paediatr 1995; 84: 894-898.
12. Levine LS Congenital adrenal hyperplasia. Pediatr Rev 2000; 21: 159-160.
13. Einaudi S, Lala R, Corrias A. Auxological and biochemical parameters in assessing treatment of infants and toddlers with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol 1993; 6: 173-178.
14. Hauffa BP, Winter A, Stolecke H. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Klin Pädiatr 1997; 209: 71-77.
15. Migeon CJ, Wisniewski AB. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations. Endocrinol Metab Clin N Am 2001; 30: 193-206.
16. Brunelli VL, Carrera P, Monneret MP, Ferrari M, Chiumello G, Forest MG. 21-Deoxycortisol plasma levels after ACTH stimulation and molecular characterization of Italian families with classic P450c21 deficiency: a comparative study. Horm Res 1994; 41: 2-4 (P213).
17. New MI, White P, Pang S. The adrenal hyperplasia. In: Scriver C, Beaudet A, Sly S, Valle D, eds. The Metabolic Basis of Inherited Diseases. New York: McGraw-Hill, 1989; 1881-1917.
18. Weintrob N, Dickerman Z, Sprecher E, Galatzer A, Pertzelan A. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height. Eur J Endocrinol 1997; 136: 188-195.